Investorideas.com - Biotech /Pharma Market Movers; (NYSE:BSX), (NASDAQ:BPAX), (OTCBB: UVFT), (NASDAQ: CELG) Stocks to Watch
Boston Scientific (NYSE:BSX) Agrees to Sell Neurovascular Business to Stryker; StockTrades Over 16 Millions Shares in Morning Trading
Point Roberts, WA –October 28, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot of Market Gainers for today’s trading.. Bullish trading in some of the stocks includes Boston Scientific Corporation. (NSYE: BSX), one of the top advancing stocks on the NYSE currently trading at 6.3220, up 0.0120 (0.19%) on over 16 million shares.
Biotech /Pharma Sector Trading Snapshot: (as of time of release October 28th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.54, up 0.01 (0.65%)
Boston Scientific Corporation. (NYSE:BSX) trading at $6.3220, up 0.0120 (0.19%)
UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.31 on over 500,000 shares in volume
Celgene Corporation (NASDAQ: CELG) trading at $61.52, up 2.11 (3.55%)
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
Boston Scientific Corporation. (NYSE:BSX)
Recent News; Boston Scientific Agrees to Sell Neurovascular Business to Stryker
“Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months. The Company expects to record a gain upon closing in excess of $500 million, excluding any impact of the receipt of future milestone payments. Total after-tax proceeds, assuming the achievement of these milestones, are expected to be approximately $1.2 billion. The Company expects to allocate approximately half of the net proceeds to acquisitions and the remainder to the retirement of pre-payable debt. The transaction is expected to close before the end of the year, subject to receipt of regulatory clearances and satisfaction of other customary conditions. As a result of the divestiture, the Company expects 2011 earnings per share to be diluted by approximately four to six cents on both a GAAP and adjusted basis.”
Full Article: http://finance.yahoo.com/news/Boston-Scientific-Agrees-to-prnews-3242744555.html?x=0&.v=1
About Boston Scientific Corporation. (NYSE:BSX): Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - firstname.lastname@example.org
Source - Investorideas.com